Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
16 shown of 2,399 total abstracts
  1. Abstract 65862026-09-01 · 21:15 CT · E450
    CheckMate-571: Opdivo (nivolumab) adjuvant in RCC
    S. Modi, T. Mok · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 69712026-09-04 · 16:45 CT · E450
    KEYNOTE-908: Keytruda (pembrolizumab) adjuvant in RCC
    C. Saura, S. Modi · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 66152026-09-04 · 14:45 CT · S100A
    Quality of life outcomes with Opdivo in patients with RCC
    J. Cortes, F. Andre · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 61962026-09-02 · 20:00 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in RCC
    T. Mok, J. Cortes, M. Reck · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 61762026-09-04 · 21:15 CT · S406
    Quality of life outcomes with Keytruda in patients with RCC
    L. Paz-Ares, H. Rugo, J. Cortes, et al. · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 61542026-09-02 · 15:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-699 study)
    J. Brahmer, N. Rizvi, G. Curigliano, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 64672026-09-05 · 16:00 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-889
    J. Cortes, M. Reck · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 68332026-09-05 · 20:30 CT · S100A
    KEYNOTE-154: Keytruda (pembrolizumab) 1L in RCC
    R. Herbst, H. Borghaei, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 68052026-09-03 · 16:00 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-877
    M. Reck, H. Rugo, C. Robert, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract 65402026-09-01 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-935
    C. Saura, S. Tolaney · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  11. Abstract 61382026-09-04 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-811 study)
    J. Cortes, L. Paz-Ares, F. Andre, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 69512026-09-03 · 18:15 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-814
    S. Antonia, S. Modi, H. Rugo, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 67242026-09-05 · 21:15 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in RCC
    M. Krop, M.C. Garassino, S. Antonia, et al. · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 68192026-09-03 · 19:00 CT · S406
    KEYNOTE-373: Keytruda (pembrolizumab) 3L+ in RCC
    F. Andre, S. Peters, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  15. Abstract 64972026-09-01 · 14:30 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-75
    R. Herbst, H. Borghaei, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 60952026-09-04 · 14:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-698
    L. Paz-Ares, S. Tolaney, S. Peters, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.